Beale Gary, Hollins Andrew J, Benboubetra Mustapha, Sohail Muhammad, Fox Stephen P, Benter Ibrahim, Akhtar Saghir
Centre for Genome-based Therapeutics, The Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK.
J Drug Target. 2003 Aug;11(7):449-56. doi: 10.1080/1061186042000207039.
Gene silencing nucleic acids such as ribozymes, DNA enzymes (DNAzymes), antisense oligonucleotides (ODNs), and small interfering (si)RNA rely on hybridization to accessible sites within target mRNA for activity. However, the accurate prediction of hybridization accessible sites within mRNAs for design of effective gene silencing reagents has been problematic. Here we have evaluated the use of scanning arrays for the effective design of ribozymes, DNAzymes and siRNA sequences targeting the epidermal growth factor receptor (EGFR) mRNA. All three gene silencing nucleic acids designed to be complementary to the same array-defined hybridization accessible-site within EGFR mRNA were effective in inhibiting the growth of EGFR over-expressing A431 cancer cells in a dose dependent manner when delivered using the cationic lipid (Lipofectin) delivery system. Effects on cell growth were correlated in all cases with concomitant dose-dependent reduction in EGFR protein expression. The control sequences did not markedly alter cell growth or EGFR expression. The ribozyme and DNAzyme exhibited similar potency in inhibiting cell growth with IC50 values of around 750 nM. In contrast, siRNA was significantly more potent with an IC50 of about 100 nM when delivered with Lipofectin. The potency of siRNA was further enhanced when Oligofectamine was used to further improve both the cellular uptake and subcellular distribution of fluorescently labelled siRNA. Our studies show that active siRNAs can be designed using hybridization accessibility profiles on scanning arrays and that siRNAs targeting the same array-designed hybridization accessible site in EGFR mRNA and delivered using the same delivery system are more potent than ribozymes and DNAzymes in inhibiting EGFR expression in A431 cells.
基因沉默核酸,如核酶、DNA酶(脱氧核酶)、反义寡核苷酸(ODN)和小干扰(si)RNA,其活性依赖于与靶mRNA内可及位点的杂交。然而,准确预测mRNA内的杂交可及位点以设计有效的基因沉默试剂一直存在问题。在此,我们评估了使用扫描阵列来有效设计靶向表皮生长因子受体(EGFR)mRNA的核酶、DNA酶和siRNA序列。当使用阳离子脂质(Lipofectin)递送系统递送时,设计为与EGFR mRNA内相同的阵列定义杂交可及位点互补的所有三种基因沉默核酸均能以剂量依赖性方式有效抑制EGFR过表达的A431癌细胞的生长。在所有情况下,对细胞生长的影响都与EGFR蛋白表达的剂量依赖性降低相关。对照序列未显著改变细胞生长或EGFR表达。核酶和DNA酶在抑制细胞生长方面表现出相似的效力,IC50值约为750 nM。相比之下,当与Lipofectin一起递送时,siRNA的效力显著更高,IC50约为100 nM。当使用Oligofectamine进一步改善荧光标记siRNA的细胞摄取和亚细胞分布时,siRNA的效力进一步增强。我们的研究表明,可以使用扫描阵列上的杂交可及性图谱设计活性siRNA,并且靶向EGFR mRNA中相同的阵列设计杂交可及位点并使用相同递送系统递送的siRNA在抑制A431细胞中EGFR表达方面比核酶和DNA酶更有效。